Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sanwa Kagaku Rolls Out Upasita for Secondary Hyperparathyroidism
Sanwa Kagaku Kenkyusho on August 20 launched Upasita (upacicalcet) for the treatment of secondary hyperparathyroidism in patients on dialysis following its addition to the NHI price list earlier this month. The drug was approved on June 23 and obtained NHI…
To read the full story
Related Article
BUSINESS
- Onychomycosis Drug Jublia Now Available in Germany: Kaken
May 11, 2026
- Fujifilm Bags Japan Approval for Meniscus Regenerative Therapy
May 11, 2026
- Takeda Logs Positive PII/III Results for TAK-881 in PID, Eyes FY2026 Filing
May 11, 2026
- Capricor Sues Nippon Shinyaku over US Rights to DMD Cell Therapy
May 11, 2026
- Kyowa Kirin to Consolidate Domestic Research Sites in Yokohama
May 11, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…